• Guillaume Hache, Jean Marc Rolain, Philippe Gautret, Jean-Claude Deharo, Philippe Brouqui, Didier Raoult, and Stéphane Honoré.
• Service de Pharmacie, Hôpital de la Timone, APHM, Marseille, France.
• Microb. Drug Resist. 2021 Mar 1; 27 (3): 281-290.

AbstractThe coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2, has recently emerged worldwide. In this context, there is an urgent need to identify safe and effective therapeutic strategies for treatment of such highly contagious disease. We recently reported promising results of combining hydroxychloroquine and azithromycin as an early treatment option. Although ongoing clinical trials are challenging the efficacy of this combination, many clinicians claim the authorization to or have already begun to use it to treat COVID-19 patients worldwide. The aim of this article is to share pharmacology considerations contributing to the rationale of this combination, and to provide safety information to prevent toxicity and drug-drug interactions, based on available evidence.

29 keywords...

hide…